Cost variation analysis of various brands of anti-epileptic drugs currently available in Indian pharmaceutical market
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20172727Keywords:
Antiepileptic drugs, Cost analysis, Cost variationAbstract
Background: Epilepsy is a common neurological disorder affecting about 10 million persons in India. The compliance to a particular antiepileptic drug is highly dependent on the cost of the drug which directly translates into success or failure of therapy. Hence there is a need for all clinicians to keep themselves updated with the latest prices and price variation of the commonly prescribed drugs. This study aims to analyze cost variation of various brands of anti-epileptic drugs currently available in Indian pharmaceutical market.
Methods: Current Index of Medical Specialities July-October 2016 edition was referred to know the maximum and minimum price in INR of various brands of anti- epileptic drugs in India. Further analysis was done by using Percentage Cost Variation.
Results: There is wide variation in the prices of different brands of same antiepileptic agents in Indian market. The highest % cost variation was found for diazepam 5mg tablet (374.42), followed by lorazepam 2mg tablet (213.63), carbamazepine 100mg syrup/5ml-100ml (172.58), levetiracetam 1000mg FC-tablet (168.57), lamotrigine 25mg DIS- tablet (150), clobazam 10mg tablet (147.37), clonazepam 0.5mg tablet (145.90), oxcarbazepine 150mg tablet (89.46), gabapentin 300mg capsule (71.67), valproic acid 200mg FC-tablet (58.62), divalproex sodium 500mg ER-tablet (47.82), topiramate 50mg tablet (41.66) and lowest % cost variation was of phenytoin sodium 300mg tablet (0.23).
Conclusions: The average percentage price variation of different brands of same oral anti-epileptic drug in Indian market is very wide. To counter act such cost variation, physicians should be encouraged to prescribe a medication brand with low cost. This in turn reduces the unnecessary economic burden to the patients.
Metrics
References
Banerjee TK, Ray BK, Das SK, Hazra A, Ghosal MK, Chaudhuri A, et al. A longitudinal study of epilepsy in Kolkata, India. Epilepsia. 2010;51(12):2384-91.
Walker R, Whittlesea C. In: Clinical Pharmacy and Therapeutics.5th ed. London: Churchill Livingstone; 2012.
Paunikar AP, Bhave KA. Cost analysis of oral antidepressant drugs available in India. Natl J Physiol Pharm Pharmacol. 2015;5(5):1-5.
Kuruvilla A, George K, Rajaratnam A, John KR. Prescription patterns and cost analysis of drugs in a base hospital in south India. Natl Med J India. 1994;7(4):167-68.
Ravi Shankar P, Subish P, Bhandari RB, Mishra P, Saha AC. Ambiguous pricing of topical dermatological products. A survey of brands from two South Asian countries. Journal of Pakistan Assoctn of Dermatologists. 2006;16:134-40.
McNamara JO. Pharmacotherapy of the epilepsies. In: Brunton LB, Chabner BA, Knollman BC, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics.12th Ed. New York,: McGraw- Hill; 2011:583-606.
Current Index of Medical Specialties, July- October 2016:199-206.
Jana S, Mondal P. Pharmacoeconomics: the need to sensitize undergraduate medical students. Indian J Pharmacol. 2005;37(5):277-8.
Shukla AK, Mehani R. Cost analysis of antiepileptic drugs available in India. Int J Basic Clin Pharmacol. 2016 Aug; 5(4):1636-40.
Phatak AM, Hotwani JH, Deshmukh KR, Panchal SS, Naik MS. Cost analysis of long established and newer oral antiepileptic drugs available in the indian market., Int J Med Res Health Sci. 2015;4(4):744-8.
Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: Impact on access to medicines. Indian J Pharm Sci. 2007;69(1):160‑63.
Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, et al. The implications of choice: Prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166(3):332-7.
Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: Impact on access to medicines. Indian J Pharm Sci. 2007;69(1):160-3.
World Health Organisation. Essential drugs and medicines: Drug finance. Available at: http://www.whoindia.org/EN/Section2/Section/Section160_959.html.
Reichert S, Simon T, Halm EA. Physicians' Attitudes about Prescribing and Knowledge of the Costs of Common Medications. Arch Intern Med. 2000;160:2799-803.
Sakthivel S. Access to essential drugs and medicines. In: Lal PG, editor. National Commission on Macroeconomics and Health. New Delhi: Ministry of Health; 2005:185-210.
Kumar V, Gupta NV, Kumar KA. A comparison between old and latest systems in DPCO. International Journal of Pharmacy and Pharmaceutical Sciences. 2014;6(2):19-20.
Compendium of notified ceiling prices of scheduled drugs- NPPA; 2015. Available from: http://www.nppaindia.nic.in/ceiling price.
